KDOQI (Kidney Disease Outcomes Quality Initiative)
NKF KDOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis |
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | Cardiovascular Disease in Dialysis Patients | History of KDOQI | Pediatric Bone | Anemia 2006 |
Updates 2006

Clinical Practice Guidelines and Clinical Practice Recommendations
2006 Updates
Hemodialysis Adequacy
Peritoneal Dialysis Adequacy
Vascular Access


I.  CLINICAL PRACTICE GUIDELINES FOR HEMODIALYSIS ADEQUACY

Foreword

The publication of the second update of the Clinical Practice Guidelines (CPGs) and Clinical Practice Recommendations (CPRs) for Hemodialysis represents the second update of these guidelines since the first guideline on this topic was published in 1997. The first set of guidelines established the importance of measuring the dose of dialysis in all long-term dialysis patients and the benefits of placing an arteriovenous fistula in a timely manner to reduce the complications that can occur from using either a gortex graft or a permanent catheter for long-term hemodialysis access. Several of these guidelines have been selected as clinical performance measures by regulatory agencies to drive the process of quality improvement in long-term dialysis patients.

A number of important randomized clinical trials have been performed in long-term hemodialysis patients since the publication of the first set of guidelines. The Kidney Disease Clinical Studies Initiative Hemodialysis (HEMO) Study, a National Institutes of Health (NIH)-sponsored randomized clinical trial of dialysis dose and flux, is the largest study to date performed in long-term hemodialysis patients. Results of these and other studies of long-term hemodialysis patients have been included in the literature review for this updated set of guidelines. In addition, this update includes new guidelines on the preservation of residual kidney function, the management of volume status and blood pressure, and the importance of patient education on all dialysis modalities.

This document has been divided into 3 major areas. The first section consists of guideline statements that are evidence based. The second section is a new section that consists of opinion-based statements that we are calling “clinical practice recommendations” or CPRs. These CPRs are opinion based and are based on the expert consensus of the Work Group members. It is the intention of the Work Group that the guideline statements in Section I can be considered for clinical performance measures because of the evidence that supports them. Conversely, because the CPRs are opinion based, and not evidence based, they should not be considered to have sufficient evidence to support the development of clinical performance measures. The third section consists of research recommendations for these guidelines and CPRs. We have decided to combine all research recommendations for the guidelines into 1 major section and also have ranked these recommendations into 3 categories: critical importance, high importance, and moderate importance. Our intended effect of this change in how the research recommendations are presented is to provide a guidepost for funding agencies and investigators to target research efforts in areas that will provide important information to benefit patient outcomes.

This final version of the Clinical Practice Guidelines and Recommendations for Hemodialysis has undergone extensive revision in response to comments during the public review. Whereas considerable effort has gone into their preparation during the past 2 years and every attention has been paid to their detail and scientific rigor, no set of guidelines and clinical practice recommendations, no matter how well developed, achieves its purpose unless it is implemented and translated into clinical practice. Implementation is an integral component of the KDOQI process and accounts for the success of its past guidelines. The Kidney Learning System (KLS) component of the National Kidney Foundation is developing implementation tools that will be essential to the success of these guidelines.

In a voluntary and multidisciplinary undertaking of this magnitude, many individuals make contributions to the final product now in your hands. It is impossible to acknowledge them individually here, but to each and every one of them, we extend our sincerest appreciation. This limitation notwithstanding, a special debt of gratitude is due to the members of the Work Group and their co-chairs, John Daugirdas of The University of Illinois at Chicago and Tom Depner at the University of California at Davis. It is their commitment and dedication to the KDOQI process that has made this document possible.

Adeera Levin, MD, FACP
KDOQI Chair

Michael Rocco, MD, MSCE
KDOQI Vice-Chair